Current Report Filing (8-k)
December 21 2015 - 06:11AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 20, 2015
ONCOTHYREON INC.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
001-33882 |
|
26-0868560 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
2601 Fourth Avenue, Suite 500
Seattle, Washington 98121
(Address of principal executive offices, including zip code)
(206) 801-2100
(Registrants telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.03 |
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. |
The
disclosure under Item 8.01 of this current report on Form 8-K is incorporated by reference.
On December 20, 2015, the board of directors of Oncothyreon Inc.
(the Company) approved a waiver of the deadline under the Companys bylaws for stockholders to nominate directors for election to the board at the 2016 annual meeting of stockholders. Any director nominations received by the Company
no later than the close of business on January 11, 2016 and otherwise complying with the Companys bylaws may be submitted to stockholders at the 2016 annual meeting of stockholders.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
ONCOTHYREON INC. |
|
|
By: |
|
/s/ Robert L. Kirkman |
|
|
Robert L. Kirkman |
|
|
President & Chief Executive Officer |
Date: December 21, 2015
3
Cascadian Therapeutics, Inc. (NASDAQ:CASC)
Historical Stock Chart
From Feb 2024 to Mar 2024
Cascadian Therapeutics, Inc. (NASDAQ:CASC)
Historical Stock Chart
From Mar 2023 to Mar 2024